Net profit of Bliss GVS Pharma rose 12.32% to Rs 27.25 crore in the quarter ended September 2025 as against Rs 24.26 crore during the previous quarter ended September 2024. Sales rose 12.27% to Rs 244.40 crore in the quarter ended September 2025 as against Rs 217.68 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales244.40217.68 12 OPM %13.0019.05 - PBDT48.8942.69 15 PBT40.6335.71 14 NP27.2524.26 12 Powered by Capital Market - Live News

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 6 November 2025.Powered by Capital Market - Live News

Net profit of Bliss GVS Pharma rose 107.92% to Rs 43.04 crore in the quarter ended June 2025 as against Rs 20.70 crore during the previous quarter ended June 2024. Sales rose 12.98% to Rs 207.47 crore in the quarter ended June 2025 as against Rs 183.64 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales207.47183.64 13 OPM %19.9218.69 - PBDT71.3136.92 93 PBT63.1130.07 110 NP43.0420.70 108 Powered by Capital Market - Live News

Bliss GVS Pharma will hold a meeting of the Board of Directors of the Company on 29 July 2025.Powered by Capital Market - Live News

Bliss GVS Pharma has allotted 75,250 equity shares under ESOP on 06 June 2025. Consequently, the paid up equity share capital has increased to 10,54,45,522 equity shares of Re. 1/- each aggregating Rs. 10,54,45,522 /. Powered by Capital Market - Live News